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ABSTRACT 
Trailokyasundar rasa is one of the Rasakalpa which is explained in Rasaratnasamucchaya, and is 
suggestive of its efficacy in Pandu roga. Pandu roga is a Pitta pradhanavyadhi in which Rasadhatu 
and Raktadhatu are mainly affected. According to modern texts, all disorders of vitiated digestion, 
absorption and assimilation can be considered under Pandu. According to modern texts, all 
disorders of vitiated digestion, absorption and assimilation can be considered under Pandu. 
Therefore, it can be said that Pandu is a very broad term comprising various Rasa and 
Raktpradoshajvikara such as anaemia, megaloblastic anaemia, blood disorders, leukemia’s etc.  
Material and method: On the basis of this information animal models were planned to evaluate the 
effect of self-prepared test drug. Study duration -1 month. 
Discussion and results: The activity of Trailokyasundar rasa is highly significant by reducing 
tumour volume and growth inhibition in animal models of chronic myeloid leukemia. On the 29thday 
of the experiment tumour size of the control group was 20.05 mm, comparatively in the study group, 
mean tumour size was of 5.26 mm. Also it prevented decrease in the platelet count and Hb% as 
compared to untreated mice of CML. Rate of increment of WBC’s was also comparatively reduced in 
Trailokyasundar rasa treated mice.  
KEYWORDS: Rasa aushadhis, Trailokyasundar rasa, Panduroga, Chronic Myeloid Leukemia. 
INTRODUCTION
Any scientific system can be improvised and 
can achieve fulfillment with the help of constant 
research and inventions. Even in the ancient and 
ageless Ayurvedic classics, a strong emphasis has 
been given on continuous updating and revalidation 
of acquired knowledge. Continuous research work 
goes on to find out the cause and effect relationship 
as well as the corresponding cures on various 
ailments in living being.  
Rasa Shastra, with its blend of mystical and 
medical insights, is source of valuable knowledge. 
Medical alchemy and mercurial medicines have been 
widely accepted and utilized for over a thousand 
years on the Indian subcontinent. Rasa aushadhis are 
appreciated for their smaller dosages, quicker 
effectiveness, long durability etc. Apart from their 
therapeutic efficacy in minute doses, Rasa aushadhis 
were found very effective for the preservation and 
promotion of positive health and prevention of 
diseases which is the primary aim of Ayurveda.  
Trailokyasundar rasa is one of the Rasakalpa 
which is explained in Rasaratnasamucchaya, the very 
basic Grantha of Rasashastra. The reference of the 
Trailokyasundar rasa is suggestive of its efficacy in 
Pandu roga.[1] Pandu roga is one of the most 
conspicuous diseases as per the classics, as it 
encompasses a wide spectrum of pathological events 
and so also the symptoms. It is a Pitta pradhana 
vyadhi in which Rasadhatu and Raktadhatu are 
mainly affected.[2]  
According to modern texts, all disorders of 
vitiated digestion, absorption and assimilation can be 
considered under Pandu.[3] Therefore, it can be said 
that Pandu is a very broad term comprising various 
rasa and Raktpradoshajvikara such as anaemia, 
megaloblastic anaemia, blood disorders, Leukemia’s 
etc., Leukemia implies blood cancer and is 
characterised by clonal, neoplastic proliferation of 
immature cells of haemopoetic system, which cause 
aberrant or arrested differentiation.[4] Among the 
various types of leukemia, chronic myeloid leukemia 
accounts for about 2.8% of the total cancer affected 
population. CML is one of the commonest adult 
leukemia in Indian population accounting for 30% to 
60% of all adult leukemias.[5]  
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Cancer has been recognized and 
characterized by the science of Ayurveda. Numerous 
drugs have been mentioned for the management of 
this condition. If evaluated methodically, they may 
generate some curative or supportive remedy for the 
sufferers of this disease. 
For the rational treatment of any disease 
knowledge on the mode of action of a drug, its effects 
on various body systems and the probable adverse 
effects is important. Comparing out pharmacological 
study provides such a basis.  
Thus a sincere attempt has been taken to 
assess efficacy of Trailokyasundar rasa which is 
exclusively mentioned in Rasaratnasamuchhaya 
Pandurogadhikara, in chronic myeloid leukemia by in 
vivo study, as relation between Panduroga and CML 
can be successfully interpreted. 
Material and Methods 
On the basis of this information, animal models were 
planned to evaluate the effect of test drug.  
The measures of anticancer activity are primarily the: 
(a) Reduction of tumour size and  
(b) Increase in the life span of the mice.  
In addition to the anticancer activity, the in vivo 
screen provides information on potential toxicities, 
tolerated doses and dosage regimens, and the 
spectrum of activity. 
In vivo study material 
i. SCID mice, 6–10 weeks old (Taconic Farms, mod. 
no. CB17SC-M) Medium 199 with Earle's salts, L-
glutamine and sodium bicarbonate (Invitrogen, 
cat. no. 11150-059)  
ii. Penicillin/streptomycin solution 100X (Sigma, 
cat. no. P4333)  
iii. A-33 disinfectant (Ecolab Professional Products, 
cat. no. 61122362)  
iv. 3 M Vet bond tissue adhesive (Webster 
Veterinary Supply, cat. no. 480200) v.70% 
(vol/vol) ethanol.  
v. Isoflurane, USP (Baxter).  
vi. Gauze squares. 
Study design  
i. Study centre: Tata memorial centre, Advanced 
Centre for Treatment, Research and Education in 
Cancer, Kharghar, Navi Mumbai.  
ii. Type of study: In vivo efficacy testing.  
iii. Selected animal model for study: Xenograft SCID 
mice.  
iv. Total no of SCID mice: total 12 SCID mice were 
selected for study. 6 mice for each induced 
selected chronic myeloid leukemia Cells-K562. 
These 12 mice were divided into 2 groups. 
v. Skeleton of study 
Groups: 2 groups each consisting of 6 SCID mice 
of both sex.  
 a) Study group -The test drug i.e. TSR was 
administered. 
b) Placebo group-No drug was given. 
vi. Dose Calculation 
Suitable mouse dose was calculated by referring to 
the Paget and Barnes table.  
        = Human adult dose x body surface area ratio 
convertible factor  
= 375 mg x 0.0026  
= 0.975/20 g body weight of mouse  
= 0.975 x 50 (converting to mg/kg body weight 
by multiplying with suitable factor 50)  
= 48.75 mg/kg body weight of mouse 
vii. Dose of TSR (Trailokysundar rasa) 
 48.75mg/kg weight of mouse.  
viii. Tumour model: Human Xenograft K562–
Chronic Myeloid Leukemia.   
ix. Tumour size checking: Daily by digital Vernier 
caliper.  
x. Total duration of the Study: 1 month.  
xi. Parameters for efficacy assessment: Tumour 
volume, weight loss and mortality of mice. 
Methods: Animal models preparation 
Steps 1: Preparation of cell lines 
Harvest cells were grown in monolayer 
culture during the exponential growth phase using 
trypsin or appropriate enzymes for the specific cell 
line. Suspend cells in medium plus serum. 
Quantitated the number of cells present using a 
haemocytometer. Cells were centrifuged at 225g and 
20°C for 5 min. the medium was removed and 
resuspended the cells in medium without serum at a 
concentration of 1 × 108 cells per ml of medium. 
Steps 2: Tumour Transplantation 
i) Anaesthesia was given to mice. After the mouse 
reached sufficient aesthetic depth, it was removed 
from the chamber and placed (ventral side down) in 
a properly sized nose cone. 
ii) Using gauze square saturated with 70% (vol/vol) 
ethanol, wiped the area from the mid-spine to the 
base of the tail to prepare for the incision.  
iii) Made a small, horizontal incision of 5mm in 
length, 10mm above the base of the tail, using small 
surgical scissors.  
iv) The tip of the scissors is inserted into the incision, 
directly over the flank, and opened the scissors to 
introduce a pocket in the subcutaneous space.  
v) Inserted one individual piece of tumour into the 
pocket created using forceps.  
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vi) While the pocket was still open, placed one drop 
of 100X penicillin/streptomycin solution into the 
opening.  
vii) Closed the incision site with one drop of Vet bond 
tissue adhesive. Held the tissue together for 3–5sec 
with forceps to allow for drying.  
viii) Then the cell suspension was Agitate to prevent 
the cells from settling, and withdrew from the sterile 
tube into a 1-cc TB syringe with the needle removed.  
ix) Skin of the mouse was lifted to separate it from 
the underlying muscle and injected with a 21G 
needle, 0.1ml of the cell suspension (1 × 107cells) 
subcutaneously.  
x) Animal was placed in a clean cage and observed for 
10–15 min to ensure recovery from the anesthetic.  
Preclinical study method 
Tumour transplantation: 21/10/2015  
Experiment started: 09/11/2015  
Experiment ended: 08/12/2015  
The xenograft model mice were prepared  
Total 12 severe combined immune defiant SCID 
model mice were taken for study.  
Step I- The animals were divided into 4 groups, each 
group consisting of 6 animals. 
Step II- One group was kept as control and the other 
groups were kept as treated groups. In each group 6 
rats were taken and weighed (B.T.) and numbering 
was done.  
Step III- Drug dose for human was fixed and the dose 
was converted from human dose to animal dose. Oral 
dose of Trailokyasundar rasa was given to study 
group with the help of distilled water daily. For 
control group only distilled water was administered.  
Step IV- The animals were carefully observed daily 
for tumour size and any overt changes.  
Step V -Drug suspension was given for 30 days. On 
the completion of the experiment, blood samples of 
mice of control group, study group and normal SCID 
mice i.e. of negative control group were collected for 
conducting haematological study like Hb%, total WBC 
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Observations and Results 
Table II.1: Tumour volume of control group 
Week  Days  Mouse 1  Mouse 2  Mouse 3  Mouse 4  Mouse 5  Mouse 6  
0.00  1  0.08  0.09  0.10  0.12  0.10  0.15  
0.71  5  0.20  0.18  0.13  0.26  0.18  0.23  
1.29  9  0.29  0.39  0.19  0.61  0.11  0.24  
1.71  12  0.46  0.36  0.27  1.68  0.31  0.36  
2.14  15  0.74  0.81  0.30  2.12  0.59  0.56  
2.57  18  0.87  1.14  0.31  2.59  0.86  0.77  
3.00  21  1.29  1.45  0.38  3.53  0.87  0.74  
3.57  25  1.92  2.01  0.48  4.21  1.22  1.10  
4.14  29  2.10  2.28  0.58  4.77  1.45  1.37  
Table II.2: Tumour Volume Study group 
Week  Days  Mouse 1  Mouse 2  Mouse 3  Mouse 4  Mouse 5  Mouse 6  
0.00  1  0.05  0.09  0.07  0.07  0.05  0.09  
0.71  5  0.05  0.09  0.07  0.07  0.05  0.09  
1.29  9  0.04  0.08  0.07  0.07  0.05  0.08  
1.71  12  0.03  0.07  0.07  0.06  0.04  0.04  
2.14  15  0.05  0.08  0.14  0.18  0.05  0.08  
2.57  18  0.11  0.06  0.22  0.19  0.07  0.08  
3.00  21  0.16  0.09  0.24  0.17  0.15  0.08  
3.57  25  0.29  0.18  0.36  0.31  0.24  
4.14  29  0.33  0.21  0.43  0.34  0.26  
Table II.3: Relative Tumour Volume 
Weeks  Days  Control group  Study group  
0.00  1  1.00  1.00  
0.71  5  1.86  0.98  
1.29  9  2.95  0.92  
1.71  12  5.29  0.80  
2.14  15  8.07  1.45  
2.57  18  10.30  1.87  
3.00  21  13.12  2.45  
3.57  25  17.58  4.65  
4.14  29  20.05  5.26  
Table II.4: Percentage of survival 
Weeks  Days  A  B  
0.00  1  100  100  
0.71  5  100  100  
1.29  9  100  100  
1.71  12  100  100  
2.14  15  100  100  
2.57  18  100  100  
3.00  21  100  100  
3.57  25  100  83.3  
4.14  29  100  83.3  
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Activity Criteria: T/C ≤ 0.2 is considered to demonstrate significant activity. T/C ≤ 0.42 is considered to 
demonstrate moderate activity. 
Table II 6: Haematological Parameters 
Normal SCID mice  Control group  Study group  
Haemoglobin %  15.4  14.3  14.8  
Total WBC count/cm3  1900  5800  5100  
Platelet count (Lakhs/mm3)  5.76  4.10  5.27  
1st day of the experimental study 








 Weeks  Days  A /B 
0.0  1  22.0  22.4   0.00  1  1.00  
0.7  5  22.1  22.2   0.71  5  0.53  
1.3  9  22.3  22.1   1.29  9  0.31  
1.7  12  22.0  22.3   1.71  12  0.15  
2.1  15  21.5  21.9   2.14  15  0.18  
2.6  18  20.7  21.7   2.57  18  0.18  
3.0  21  20.1  21.2   3.00  21  0.19  
3.6  25  20.2  18.2   3.57  25  0.26  
4.1  29  20.4  21.7   4.14  29  0.26  
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15th day of the experimental study 
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Last day of the experimental study 
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Animal models have been used as the front 
line in predicting efficacy and finding toxicities for 
cancer chemotherapeutic agents before entering the 
clinic. This has resulted in the developing various in 
vivo models exhibiting the traits of neoplastic 
diseases.  
Discovery of nude athymic mice that were T-
cell deficient[6] and later B-cell-deficient and T-cell-
deficient severe combined immunodeficient 
(SCID/SCID) mice allowed the routine and efficient 
transplantation and propagation of human tumour 
tissues (xenografts) in mice. These mouse strains 
allow pre cultured in vitro human cell lines to be 
propagated subcutaneously, reconstituting solid 
tumours. Human tumour tissue explants obtained 
from biopsy or autopsy could be transplanted 
directly into these strains of mice. 
Relative tumour volume 
In K562 cancer cell line study 12 xenograft 
model mice were taken out of which 6 were in 
control group, 6 in study group. In control group and 
study group, the tumour size was observed 4-5mm at 
7 days after tumour transplantation. On first day of 
the study, for ease of calculation, tumour size of all 
the mice was taken to be 1 mm.  
The test drug was administered orally, daily 
for up to one month to the study group. On fifth day 
of the study, increase in mean tumour size of mice in 
control group was observed from 1mm to 1.86mm. 
whereas in mice of study group the tumour size 
reduction was notable. Tumour size was reduced 
from 1mm to 0.98mm and further reduction in 
tumour size was seen up to 12th day of the study. 
Tumour was reduced up to 0.80mm. concurrently in 
control group, significant increase in size was 
observed i.e. 5.29mm on 12th day. Progressive 
increase in the tumour size of control group was 
observed. On the 29th day of the experiment tumour 
size of the control group was 20.05mm. 
comparatively in the study group, mean tumour size 
was of 5.26mm. (Table II.3)  
In chart no II.3, the difference between 
relative tumour volumes of both the groups was 
found to be significant.  
Animal body weight and survival 
No noticeable change in body weight of mice 
in both the groups (i.e. control group and study 
group) was observed. 100% survival was seen in 
control group whereas due to death of one mouse on 
25th day of the study, the survival rate in study group 
was observed to be 83.3% (Table II.4 and Table II.5). 
Cause of the death of the single mouse in study group 
remained unidentified.  
Haematological investigations 
Blood samples of SCID mice were collected on 
29th day of the study. For comparison blood samples 
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from normal SCID mice i.e. negative control were also 
collected. Haemoglobin percentage, total WBC count 
and platelet count were calculated.  
Significant fall in the haemoglobin percentage 
of control group was observed as compared to that of 
normal mice. In the mice of study group, Hb was 
14.8% which is closer to that of normal standard 
value in SCID mice. (Chart no.II.)  
Conspicuous increase in WBC count of the 
control group i.e. up to 5800, shows prognosis of CML 
in mice, as WBC count of normal SCID mice was 1900. 
It was slightly controlled in study group mice as the 
WBC count was 5100. (Chart no.II.7.2)  
Platelet count of normal SCID mice was 5.75 
lakhs/mm3, whereas it was reduced in control group 
mice. Platelet count was 4.10 lakhs/mm3 in control 
group and in study group, it was maintained at 5.27 
lakhs/mm3. (Chart no.II.7.3)  
Hb, WBC and platelet count demonstrates 
that prognosis of CML was controlled in the drug 
treated group as compared to mice in control group.  
T/C values from RTV data 
As per the international norms of cancer 
research, if the treatment/control from RTV data is 
≤0.2 then the activity of drug or element is 
considered as highly significant and if it is > 0.2 to ≤ 
0.4 then is considered to demonstrate moderate 
activity. In Table no.II.6, the highlighted area shows 
T/C value from RTV to be below 0.2. So it is highly 
suggestive of significant activity of TSR on CML 
induced Xenograft SCID mice. This is in accordance 
with the criteria for assessment of herbo-mineral 
compound. For herbal drug it is T/C ≤ 0.4. But, herbo-
mineral drug formulation there is no such criteria 
available yet. So in the current study, results were 
determined as per the norms for chemical element.  
From the obtained results it can be said that, 
the activity of Trailokyasundar rasa is highly 
significant by reducing tumour volume and growth 
inhibition in animal models of chronic myeloid 
leukemia. Also it prevented decrease in the platelet 
count and Hb% as compared to untreated mice of 
CML. Rate of increment of WBC’s was also 
comparatively reduced in Trailokyasundar rasa 
treated mice.  
CONCLUSION 
Trailokyasundar rasa is found highly 
significant in reducing tumour volume and inhibiting 
the growth of CML cells. Also it restores the 
haematological components as compared to control 
group. 
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